Cardiovascular Endocrinology & Metabolism最新文献

{"title":"Evaluating the cardio-protective effects of <i>Momordica balsamina</i> in a diet-induced prediabetic rats.","authors":"Bongiwe Khumalo, Angezwa Siboto, Akinjide Moses Akinnuga, Ntethelelo Sibiya, Andile Khathi, Phikelelani Siphosethu Ngubane","doi":"10.1097/XCE.0000000000000359","DOIUrl":"10.1097/XCE.0000000000000359","url":null,"abstract":"<p><strong>Background: </strong>Cardiovascular disease (CVD) is the predominant cause of morbidity and mortality among patients with type 1 or type 2 diabetes. The association between hyperglycemia and intracellular metabolic changes can result in oxidative stress, low-grade inflammation, and endothelial dysfunction. The management of hyperglycemia and prediabetes-associated vascular complications rely on pharmacotherapy and lifestyle intervention strategies. Research investigated the cardio-protective effects of <i>Momordica balsamina</i> in a diet-induced prediabetic rats.</p><p><strong>Materials and methods: </strong>Prediabetes was induced using a laboratory established protocol in male Sprague Dawley rats. Thereafter, <i>M. balsamina</i> (250 mg/kg) was administered to prediabetic rats once a day every third day in the presence or absence of dietary intervention. Blood pressure and plasma glucose concentration were monitored throughout the study. Blood and tissue were collected for biochemical analysis.</p><p><strong>Results: </strong><i>M. balsamina</i> with or without dietary intervention resulted into a reduction in mean arterial blood pressure. In addition, there was a significant decrease in the heart tissue malondialdehyde and increased plasma superoxide dismutase and glutathione peroxidase concentration. Furthermore, there was a decrease in plasma triglycerides, low-density lipoprotein with an increased high-density lipoprotein concentration Lastly, <i>M. balsamina</i> with or without dietary intervention demonstrated a reduced plasma tumor necrosis factor alpha and reduced interleukin-6 concentrations in the absence of dietary intervention.</p><p><strong>Conclusion: </strong><i>M. balsamina</i> coupled with or without dietary intervention decreased the risk of developing cardiac injury, thus preventing cardiovascular disease in prediabetes. Therefore, this medicinal plant may be a beneficial therapeutic agent in the prevention of prediabetic cardiovascular complications.</p>","PeriodicalId":43231,"journal":{"name":"Cardiovascular Endocrinology & Metabolism","volume":"15 2","pages":"e00359"},"PeriodicalIF":1.4,"publicationDate":"2026-04-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13090081/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147724274","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Proteomics analysis of empagliflozin in patients without diabetes or overt heart failure from empagliflozin and cardiac remodeling in people without diabetes CardioLink-7 randomized clinical trial.","authors":"Wei-Siang Chen, Ning-I Yang, Subodh Verma, Min-Hui Liu, Kun-Yi Chien, Chia-Wei Chen, Adrian Quan, Hwee Teoh, Andrew T Yan, Kim A Connelly, Yu-Hsiang Juan, Ching-Wen Chang, C David Mazer, Chao-Hung Wang","doi":"10.1097/XCE.0000000000000358","DOIUrl":"10.1097/XCE.0000000000000358","url":null,"abstract":"<p><strong>Background: </strong>Sodium-glucose cotransporter 2 (SGLT2) inhibitors reduce cardiovascular and cardiorenal events in people across the spectrum of heart failure. Using proteomics analysis, this study investigated the potential benefits of SGLT2 inhibitors in primary prevention at a protein level in patients without diabetes or heart failure.</p><p><strong>Methods: </strong>This is a sub-study of the EMPA-HEART 2 CardioLink-7 trial, which randomized people without diabetes or clinically overt heart failure but with risk factors for adverse cardiac remodeling to empagliflozin (10 mg/day) or placebo for 6 months. Blood samples were collected during the randomization visit and at the 6-month follow-up visit for proteomics analysis. Our investigation involved two phases of approach: discovery and verification.</p><p><strong>Results: </strong>Samples from individuals assigned to empagliflozin (<i>n</i> = 21) and placebo (<i>n</i> = 22) (median baseline N-terminal pro-B-type natriuretic peptide levels: 33.9 and 78.4 pg/ml, respectively) were analyzed. In the discovery phase, 28 of 1622 proteins fulfilled our threshold for being differentially expressed at 6 months. Ten proteins were verified, including calmodulin-like protein 5, desmoplakin, hornerin, peroxiredoxin-2, macrophage colony-stimulating factor 1 receptor, endosialin, high-temperature requirement serine protease A1, immunoglobulin epsilon heavy chain, proteasome subunit beta type-5, and cerebellin-4. Compared to the placebo group, the expression of these proteins from baseline to 6 months was all significantly decreased in the empagliflozin group. Their functions involved ion channel signaling, fibrosis, oxidative stress, inflammation, apoptosis, immune response, proteolysis, and neuromodulation.</p><p><strong>Conclusion: </strong>Empagliflozin modified multiple biologically relevant pathways in the nondiabetes and non-heart failure setting. These findings should be considered hypothesis-generating and warrant validation in larger, adequately powered studies.</p>","PeriodicalId":43231,"journal":{"name":"Cardiovascular Endocrinology & Metabolism","volume":"15 2","pages":"e00358"},"PeriodicalIF":1.4,"publicationDate":"2026-04-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13308925/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148346621","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Adrenal adenomata displaying mild autonomous cortisol secretion: a service evaluation of cardiometabolic profile routinely screened patients.","authors":"Adrian H Heald, Callum Stables, Sarah Jamil, Waseem Majeed, Sangeeth Veluchamy, Rupinder Kochhar, Akheel Syed, Rajshekhar Mudaliar, Fahmy Hanna, David Marshall, Ian Laing, Mark Livingston, Anthony A Fryer, Adhithya Sankar, Brian Keevil","doi":"10.1097/XCE.0000000000000357","DOIUrl":"10.1097/XCE.0000000000000357","url":null,"abstract":"<p><strong>Introduction: </strong>A proportion of adrenal adenomata exhibit autonomous cortisol secretion, now termed mild autonomous cortisol secretion (MACS), as defined by post-1mg overnight dexamethasone suppression test (ONDST) cortisol 51-137 nmol/l. Here, we characterized the cardiometabolic profile of MACS.</p><p><strong>Methods: </strong>Clinical records of 98 individuals with adrenal adenomata were examined. Subcategorization into MACS1 (ONDST cortisol of 50-137 nmol/l) and MACS2 (ONDST cortisol of >137 nmol/l was created to take account of individuals with ONDST cortisol of more than 137 nmol/l and no diagnosis of Cushing's syndrome.</p><p><strong>Results: </strong>Diagnosis of MACS1 associated with a higher diagnosis rate of cardiovascular disease (CVD) (17.7% MACS1) vs. non-MACS = nonfunctioning adenoma (NFA) (3.7%) (<i>P</i> = 0.009) and higher rates of prescription of lipid-lowering agents (51.6%) vs. (29.6%) (<i>P</i> = 0.01). ONDST cortisol levels in MACS1 patients correlated with a more adverse lipid profile (for higher low-density lipoprotein cholesterol, <i>r</i> ² = 0.404, <i>P</i> = 0.007; high-density lipoprotein cholesterol <i>r</i> ² = -0.346, <i>P</i> = 0.023; for higher serum triglycerides <i>r</i> ² = 0.282, <i>P</i> = 0.02) in spite of higher rates of statin prescribing. There was a gradient of increasing numbers of antihypertensives prescribed, going from non-MACS NFA to MACS1 to MACS2. Dunn's post hoc analysis indicated an overall more adverse lipid profile in MACS1.</p><p><strong>Conclusion: </strong>The positive direction of associations between serum cortisol and lipid measures highlights that MACS carries a metabolically adverse lipid profile. Diagnosis of MACS was associated with a higher diagnosis rate of CVD and appropriately higher rates of prescription of lipid-lowering agents and a greater number of antihypertensive agents prescribed. The question remains about whether a specific directed treatment of MACS should be offered beyond risk-factor-mitigating management.</p>","PeriodicalId":43231,"journal":{"name":"Cardiovascular Endocrinology & Metabolism","volume":"15 1","pages":"e00357"},"PeriodicalIF":1.4,"publicationDate":"2026-03-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12956158/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147356940","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Evening salivary cortisone for evaluation of hypercortisolaemia: evaluation and implications.","authors":"Yasitha Illangasekera, Anish Patil, Hannah Brown, Mathilde Mordaunt, Tara Keaney, Waseem Majeed, Rupinder Kochhar, Akheel A Syed, Rajshekhar Mudaliar, Adhithya Sankar, Fahmy Hanna, David Marshall, Joanna Borzomato, Mark Livingston, Brian Keevil, Adrian H Heald","doi":"10.1097/XCE.0000000000000355","DOIUrl":"10.1097/XCE.0000000000000355","url":null,"abstract":"","PeriodicalId":43231,"journal":{"name":"Cardiovascular Endocrinology & Metabolism","volume":"15 1","pages":"e00355"},"PeriodicalIF":1.4,"publicationDate":"2026-02-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12928863/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147285420","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Genetic, neuropeptidergic, and cardiometabolic interplay in female central precocious puberty.","authors":"Aygun Khaleddin Musayeva, Mahira Firudinkizi Amirova","doi":"10.1097/XCE.0000000000000343","DOIUrl":"10.1097/XCE.0000000000000343","url":null,"abstract":"<p><p>Central precocious puberty (CPP) results from premature reactivation of the hypothalamic-pituitary-gonadal axis and is increasingly recognized as a systemic condition linked to cardiometabolic health. Genetic mutations, particularly in imprinted genes such as <i>MKRN3</i> and <i>DLK1</i>, are major monogenic causes of familial CPP, while rare activating variants in <i>KISS1</i> and <i>KISS1R</i> highlight the pivotal role of kisspeptin signaling. Neuropeptides, including kisspeptin and neurokinin B, are central to pubertal regulation. Advances in clinical assessment, biochemical markers, pelvic ultrasound, and genetic testing have improved diagnostic precision, though differentiating CPP from benign variants remains challenging. Gonadotropin-releasing hormone analogs remain the gold standard for halting progression and optimizing adult height, while novel neuropeptide modulators show promise. Beyond growth outcomes, accumulating evidence indicates significant cardiometabolic sequelae, underscoring the importance of early, precision-guided intervention. Integrating genomic, neuropeptidergic, and metabolic insights can refine diagnosis, guide therapy, and potentially mitigate lifelong cardiovascular risk in affected females.</p>","PeriodicalId":43231,"journal":{"name":"Cardiovascular Endocrinology & Metabolism","volume":"14 3","pages":"e00343"},"PeriodicalIF":1.1,"publicationDate":"2025-08-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12398385/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144973249","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Pitavastatin-induced cholesterol deficiency elevates serum biomarkers associated with statin-related adverse effects in rats.","authors":"Sakhavat Abolhasani, Yasin Ahmadi, Hossein Mozafar Saadati","doi":"10.1097/XCE.0000000000000326","DOIUrl":"10.1097/XCE.0000000000000326","url":null,"abstract":"<p><strong>Background: </strong>Statins are prescribed to manage hypercholesterolemia. While effective, these medications are associated with adverse effects, particularly myopathy. Cholesterol is essential for muscle function, and its depletion - especially by lipophilic statins - may contribute to muscle damage. Pitavastatin mainly targets hepatic cholesterol synthesis with minimal direct effect on muscle tissue. This study investigates the impact of pitavastatin-induced cholesterol depletion on skeletal muscle.</p><p><strong>Methods: </strong>Male Sprague-Dawley rats were divided into three groups: control (<i>n</i> = 10), pitavastatin-treated on a normal diet (ND, <i>n</i> = 10), and pitavastatin-treated on a high-cholesterol diet (HCD, <i>n</i> = 10). Pitavastatin (15 mg/kg/day) was administered orally for 6 weeks. Serum lipid profile, hepatic injury markers (alanine aminotransferase, aspartate aminotransferase), muscle damage markers (creatine phosphokinase), and bone metabolism indicators (alkaline phosphatase, calcium, phosphate, or magnesium) were analyzed.</p><p><strong>Results: </strong>Pitavastatin significantly reduced total cholesterol and low-density lipoprotein cholesterol in both ND and HCD groups (<i>P</i> < 0.05) without affecting triglycerides, high-density lipoprotein cholesterol, or very-low-density lipoprotein. The ND group showed significant elevations in alanine aminotransferase, aspartate aminotransferase, and creatine phosphokinase compared to the control and HCD groups (<i>P</i> < 0.05), suggesting cholesterol depletion contributes to hepatic and muscle damage. The HCD group exhibited reduced elevations in these markers, indicating a protective role of dietary cholesterol. No significant differences were observed in alkaline phosphatase, calcium, phosphate, or magnesium. Bivariate correlation analysis showed an inverse association between total cholesterol and liver enzyme markers.</p><p><strong>Conclusion: </strong>Pitavastatin-induced cholesterol depletion increased hepatic and muscle damage markers. Dietary cholesterol may mitigate these effects, highlighting the importance of cholesterol homeostasis in statin therapy.</p>","PeriodicalId":43231,"journal":{"name":"Cardiovascular Endocrinology & Metabolism","volume":"14 2","pages":"e00326"},"PeriodicalIF":1.4,"publicationDate":"2025-03-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11893090/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143597971","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impact of obesity on low density lipoprotein plasmatic levels 6 weeks after an acute coronary syndrome.","authors":"Elise Bourgeois, Daylale Benchalkha, Morgane Brobst, Fanchon Herman, Nicolas Molinari, Cyril Breuker, Nicolas Chapet, François Roubille, Ariane Sultan","doi":"10.1097/XCE.0000000000000320","DOIUrl":"10.1097/XCE.0000000000000320","url":null,"abstract":"<p><strong>Introduction: </strong>Cardiovascular disease is the leading cause of death. One of the main factors is obesity, which is on the rise. LDL levels below 0.55 g/L are recommended after ACS. To date, there are no specific recommendations for obese subjects.</p><p><strong>Objective: </strong>The primary objective was to assess the impact of obesity on LDL-c target attainment 6 weeks after initiation of statin therapy in subjects admitted for ACS. The secondary objectives were to assess the evolution of cholesterol levels and to characterize lipid-lowering treatments.</p><p><strong>Methods: </strong>The single-center observational study took place at Montpellier University Hospital and included patients admitted to the ICU for ACS not treated with statins (T0). Biological tests were performed at 6 weeks. At 3 months, a telephone call was made by two pharmacists to collect the results of their biological work-up and any therapeutic modifications.</p><p><strong>Results: </strong>The results were analyzed on 286 patients. A total of 39.5% were overweight and 22.7% obese. After hospitalization, 95.4% were prescribed statins. At 6 weeks, LDL cholesterol averaged 1.58 mmol/L, lower in subjects with a BMI greater than 30 kg/m² (1.32 mmol/L). On average, 49.46% of subjects reached the LDL cholesterol target, with obese subjects achieving a higher rate of 64.9%. There was no significant difference in the prescription of lipid-lowering treatments between the two groups.</p><p><strong>Conclusion: </strong>Despite high-intensity statin prescription, the target was achieved by 67.6% of obese subjects and 44.8% of subjects with a BMI of less than 30 kg/m². This shows that post-SCA management needs to be reinforced for the general population.</p>","PeriodicalId":43231,"journal":{"name":"Cardiovascular Endocrinology & Metabolism","volume":"14 1","pages":"e00320"},"PeriodicalIF":1.4,"publicationDate":"2024-12-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11627480/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142802569","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The association between consumption of dairy products and risk of type 2 diabetes.","authors":"Soroor Fathi, Mahsa Vahdat, Zahra Saeedirad, Naeemeh Hassanpour Ardekanizadeh, Mahdi Mousavi Mele, Soheila Shekari, Khadijeh Abbasi Mobarakeh, Hanieh Shafaei, Alireza Mosavi Jarrahi, Asma Rajabi Harsini, Sara Khoshdooz, Maryam Gholamalizadeh, Hamideh YazdiMoghaddam, Saeid Doaei","doi":"10.1097/XCE.0000000000000318","DOIUrl":"10.1097/XCE.0000000000000318","url":null,"abstract":"<p><strong>Background: </strong>The effects of dairy products on type 2 diabetes mellitus (T2DM) are unclear. Some studies have revealed the beneficial effects, whereas others found harmful effects of dairy products on the risk of T2DM. The objective of the present study was to investigate the association of different types of dairy products with risk of T2DM in Iranian adults.</p><p><strong>Methods: </strong>This cross-sectional study included a total of 4241 individuals. Among these participants, 1804 were diagnosed with T2DM or prediabetes, whereas the remaining 2437 individuals were without T2DM. A validated food frequency questionnaire was used to assess the consumption of different types of dairy products.</p><p><strong>Results: </strong>A positive association was found between T2DM with dietary intake of milk [odds ratio (OR): 1.16, 95% confidence interval (CI): 1.11-1.23, <i>P</i> = 0.008] and cheese (OR: 1.90, 95% CI: 1.41-2.29, <i>P</i> = 0.001) after adjustment for age, sex, physical activity, BMI, education level, energy, and fat intake. There was no significant association between T2DM and dietary intake of total dairy, yogurt, ayran (yogurt drink), and curd.</p><p><strong>Conclusion: </strong>A positive association was found between the consumption of some dairy products including milk and cheese and the risk of T2DM. Further longitudinal studies are warranted to approve this finding.</p>","PeriodicalId":43231,"journal":{"name":"Cardiovascular Endocrinology & Metabolism","volume":"14 1","pages":"e00318"},"PeriodicalIF":1.3,"publicationDate":"2024-12-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11620717/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142802575","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The association between hypertension and different types of dietary carbohydrates.","authors":"Alireza Rafieipour, Mobina Zeinalabedini, Soheila Shekari, Fatemeh Azaryan, Zahra Salimi, Naeemeh Hassanpour Ardekanizadeh, Zahra Mahmoudi, Atefeh Kohansal, Ali Shamsi-Goushki, Maryam Gholamalizadeh, Seyed Alireza Mosavi Jarrahi, Sara Khoshdooz, Saeid Doaei, Akram Kooshki","doi":"10.1097/XCE.0000000000000317","DOIUrl":"10.1097/XCE.0000000000000317","url":null,"abstract":"<p><strong>Background: </strong>Hypertension is the most prominent and well acknowledged chronic disease in developed countries and is a significant contributor to global mortality. The present study aimed to investigate the association between hypertension and different types of dietary carbohydrates.</p><p><strong>Method: </strong>This cross-sectional study was conducted on 4184 people aged 35-70, including 1239 patients with hypertension and 2945 subjects with normal blood pressure (BP) in Sabzevar, Iran. The dietary intake data were collected through the administration of a semiquantitative Food Frequency Questionnaire. Utilizing Nutritionist IV software, dietary glucose, fructose, simple sugar, carbohydrate, and galactose consumption were evaluated.</p><p><strong>Results: </strong>A direct association was found between dietary glucose and BP (odds ratio: 1.02; 95% CI: 1.01-1.05; <i>P</i> = 0.04). This association remained significant after adjusting for age. Further adjustments for education, marital status, job, physical activity, and BMI, and additional adjustments for energy intake did not change the results.</p><p><strong>Conclusion: </strong>In summary, the present study identified a significant association between hypertension and dietary intake of glucose. Considering that carbohydrates are an essential part of the diet worldwide, these findings can be valuable in formulating dietary interventions for hypertensive patients.</p>","PeriodicalId":43231,"journal":{"name":"Cardiovascular Endocrinology & Metabolism","volume":"13 4","pages":"e00317"},"PeriodicalIF":1.3,"publicationDate":"2024-11-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11913412/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143651198","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Does dietary intake of vitamin A and beta-carotene increase the risk of hypertension?","authors":"Sasan Rahmanian, Zahra Salimi, Mohammad Masoumvand, Zohre Aghakhani Nejad, Mohamadtaghi Ghorbani Hesari, Seyed Reza Mirshafaei, Mohammad Keshavarz Mohammadian, Khadijeh Abbasi Mobarakeh, Masoomeh Ataei Kachooei, Ali Shamsi-Goushki, Sara Khoshdooz, Parsa Bahmani, Saeid Doaei, Akram Kooshki, Maryam Gholamalizadeh","doi":"10.1097/XCE.0000000000000316","DOIUrl":"10.1097/XCE.0000000000000316","url":null,"abstract":"<p><strong>Background: </strong>Hypertension (HTN) is a major global public health issue influenced by genetics and lifestyle factors such as diet and psychological stress. Previous research suggests a potential link between HTN and dietary vitamin A intake. This study aims to explore the association between HTN and the intake of various forms of vitamin A.</p><p><strong>Methods: </strong>This cross-sectional study was conducted on 1239 patients with HTN and 2945 normotensive individuals aged 35-70 years in Sabzevar, Iran. Dietary vitamin A intake was assessed using the Nutritionist IV software and a food frequency questionnaire.</p><p><strong>Result: </strong>A positive association was found between HTN with total vitamin A intake [odds ratio (OR): 1.03, 95% confidence interval (CI): 1.01-1.05, <i>P</i> = 0.04] and β-carotene intake (OR: 1.03, 95% CI: 1.02-1.05, <i>P</i> = 0.03) after adjusting for age and sex. These associations remained statistically significant after adjusting for physical activity and BMI. The association between HTN and β-carotene intake remained significant after additional adjustment for calorie intake. No significant association was observed between dietary retinol intake and HTN.</p><p><strong>Conclusion: </strong>Increased dietary intake of vitamin A and β-carotene may be associated with a higher risk of HTN. Further longitudinal studies are needed to confirm these findings and elucidate the underlying mechanisms.</p>","PeriodicalId":43231,"journal":{"name":"Cardiovascular Endocrinology & Metabolism","volume":"13 4","pages":"e00316"},"PeriodicalIF":1.3,"publicationDate":"2024-11-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11884834/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143574310","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}